Stem Cell And Regenerative Therapy Market to witness a healthy growth by 2024 – Guru Online News

The globalstem cell and regenerative medicines marketshould grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

Get More Information about :https://www.trendsmarketresearch.com/report/sample/11723

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Request for Discount :https://www.trendsmarketresearch.com/report/discount/11723

Summary

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

Read the original:
Stem Cell And Regenerative Therapy Market to witness a healthy growth by 2024 - Guru Online News

Works complete on ground-breaking medical research centre at University of Nottingham – East Midlands Business Link

Midlands contractor G F Tomlinson is celebrating the completion of a pioneering project at the University of Nottingham delivering a major expansion to the Centre for Biomolecular Sciences that will house vital research into the treatment for cancer.

As part of the works, a new state-of-the-art facility has been constructed, located on the University Park Campus. This will provide world-class laboratories, offices and meeting rooms for academic and postgraduate students and staff, for research into identifying new breakthroughs in the treatment and diagnosis of serious diseases such as cancer, cardiovascular, liver, bone and respiratory conditions.

Spanning five floors, the 65,000 sq ft new-build flexible research centre is the third phase of the development by the University to its Centre for Biomolecular Sciences. The centre has been constructed to satisfy demands for increased biomolecular research and re-enforces the University of Nottinghams position as a global hub for breakthrough medical research.

The new facility will allow several research groups, previously spread across six of the Universitys sites, to work under the same roof. This includes groups in Stem Cell Biology and Regenerative Medicine, Cancer Science, Respiratory Genetics and Pharmacology.

This is the eighth project completed at the University of Nottingham by G F Tomlinson; with the company currently working on a number of educational and public sector projects across the Midlands.

The new centre at the University of Nottingham was built with sustainability at the forefront throughout; being constructed to the Building Research Establishment Environmental Assessment Method (BREEAM) standard of excellent.

Specialist curtain walling has been used for the building to provide high-level insulation while also blending into the external building faade. There has also been the installation of rooftop plantrooms, two green roofs, photovoltaic panels and brise-soleil sun screens ensuring undesired heat and light do not enter the building.

A bridge link has also been built to connect the centre at its third floor to the adjacent Boots Science Building. This is as well as a new bridge from the existing Centre for Biomolecular Sciences to the new expansion.

G F Tomlinson started works on site in 2017, investing in several social value initiatives throughout the project. This included offering two 40-metre tower cranes for high-rise fire training for officers from Nottinghamshire Fire and Rescue Service, as well as hosting a Bowel Cancer Awareness Day for G F Tomlinson employees, the supply chain and University staff.

The contractor has provided 450 hours of work experience, as well as investing over 33,000 hours into social value throughout the project. This includes an investment of 15,371 hours into skills and training; 1,063 hours into environmental protection; 16,961 hours for community support; and 325 hours into sustainable procurement.

Managing Director of G F Tomlinson, Andy Sewards said: Having worked with the University of Nottingham on a number of projects, it is incredible to see the impact that the works have across the campus and for its many students and staff members. Their breakthrough research into biomolecular sciences is revolutionary, and the new centre will help increase their capability as well as the profile of the University.

As a regional contractor, delivering higher education projects is key to our business and we are proud to say we have delivered such an important facility for the future of medical research. Well done to all the team for their hard work and dedication, which has evidently paid off to deliver this amazing project within the initially predicted timeframe.

G F Tomlinson worked alongside Buro Four as project managers, cost managers Gleeds, architects Benoy, WSP Safety Ltd as the principle designer and M&E engineers.

Senior Capital Projects Manager at the University of Nottingham, James Hale added: It is great to see the expansion complete and further our vital offering at the Centre for Biomolecular Sciences. The new world-class facilities will allow us to meet the demand for increased biomolecular research, and strengthens the Universitys strong reputation as an international centre in the field. I would like to thank all those involved in the project, including G F Tomlinson, for helping bring our plans for the University to life.

Director of Buro Four Project Managers, David Boles said: We are incredibly proud to have project managed this exciting project which will provide such opportunity for the University, students, region and the field of Biomolecular Sciences. We particularly enjoy working with universities to deliver complex and highly functional science and research facilities where collaboration is at the heart of strategy, and this project meets all of those aspirations.

See the article here:
Works complete on ground-breaking medical research centre at University of Nottingham - East Midlands Business Link

ISSCA Faculty Honored with Health Sciences Awards at Conference Held at the University of Miami – PRUnderground

Three faculty members with the International Society for Stem Cell Application (ISSCA) were honored with awards at the organizations recent regenerative medicine conference held at the University of Miami on October 24-27. The awards were sponsored by the Sociedad Internacional en Investigacin, Salud, Desarrollo Empresarial y Tecnologas (SISSDET) and lauded the honorees for their commitment to leadership and education in the field of regenerative medicine.

The three recipients of the awards are Dr. Damian Ariel Siano, Dra. Maritza Novas, and Dra. Silvina Pastrana. All three have continued to partner with the ISSCA and have notable contributions to the field by offering courses in regenerative medicine, helping thousands of doctors around the world add stem cells therapies to their medical practices.

Dr. Damian Ariel Siano is an orthopedic physician from Argentina who has dedicated his professional life to treat sports injuries. He is one of the most renowned sports medicine specialists in South America. Dr. Siano currently works with one of the most famous soccer teams in Argentina, using cell therapies to help professional athletes avoid unnecessary surgery and recuperate quicker from injuries.

Dra. Maritza Novas currently serves as the Director of Research and Development for the Global Stem Cells Group. For the past 10 years, she has dedicated herself to educating doctors in the latest stem cells advancements and conducting stem cell research. Dra. Novas has visited all continents, sharing her knowledge as a stem cells practitioner and researcher.

Dra. Silvina Pastrana is one of the first doctors that helped form the ISSCA. She has become a visionary in the field and is noted for creating her own stem cells protocols and using complementary therapies to get better results in patient who utilize cell therapies. Dra. Pastrana combines both ozone and vitamin C therapies before employing stem cell protocols, obtaining excellent results in treating patients with arthritis.

The ISSCA is committed to helping physicians who want to add regenerative medicine to their practices gain the education and tools to do that, said Benito Novas, Vice President of Public Relations for ISSCA. The three doctors recognized at our recent event at the University of Miami are prime examples of the high-quality instructors that physicians can anticipate working with when then attend one of our conferences. Congratulations to our faculty on receiving this prestigious award, and thank you to SISSDET for recognizing their accomplishments.

ISSCA is a global leader in stem cells research, applications, and education, partnering with major global institutions and locations worldwide to host its independent medical congresses. To learn more about the ISSCA and its all of its past and upcoming events, visit http://www.issca.us

About International Society for Stem Cells Applications

The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine. Their code of ethics emphasizes principles of morals and ethical conducts.

At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerativemedicine and make it available to benefit patients both nationally and globally.

For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com

Continued here:
ISSCA Faculty Honored with Health Sciences Awards at Conference Held at the University of Miami - PRUnderground

BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting – GlobeNewswire

NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Companys Chief Operating and Chief Medical Officer Ralph Kern MD MHSc will present at the 7th International Stem Cell Meeting, which is hosted by the Israel Stem Cell Society. The Conference will be held November 12-13, in Tel Aviv, Israel.

Ralph Kern, MD, MHSc, said: I welcome the opportunity to participate in the 7th International Stem Cell Meeting where I will share the advances BrainStorm has made with NurOwn. It is a privilege to participate and to exchange ideas with many of the international scientific leaders in stem cell research.

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company's website at http://www.brainstorm-cell.com

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Original post:
BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting - GlobeNewswire

Learn How You Can Treat Your Pain with Regenerative Medicine! – Patch.com

Have you wondered about new and innovative pain treatment processes that could change your quality of life?

Join us Monday, December 16, 7PM at the Woodbridge Main Library as Manisha Chahal, MD of Edison-Metuchen Orthopaedic Group discusses Regenerative Medicine to Treat Pain. Dr. Chahal will walk us through the promising results of regenerative medicine with a focus on platelet rich plasma and stem cells. She will explain how this process works and the evidence to support this cutting edge science. Dr. Chahal will also describe the best practices to go about and the indications to look out for. She will disclose how to avoid misleading providers and illegitimate products.

About Dr. Manisha Chahal, MD

Dr. Manisha Chahal is a board certified Interventional Pain Management Physician who specializes in minimally invasive procedures for pain.

Dr. Chahal treats the following conditions: headache, lower back pain, joint pain, neck pain, CRPS, postherpetic neuralgia, abdominal wall pain, pelvic pain, coccydynia, and sciatica.

Additionally, Dr. Chahal also performs the following procedures: spinal cord stimulators, regenerative medicine (PRP & stem cell injections), Botox for migraines, cervical epidural steroid injection, lumbar translaminar or transforaminal epidural steroid injections, cervical and lumbar facet rhizotomy, discograms, nerve blocks (ultrasound & C-arm guided), knee genicular blocks & rhizotomy, joint injections, trigger point injections, and qutenza treatment (chemical rhizotomy) for PHN pain.

She received her medical degree from Howard University where she was awarded a Trustee Scholarship for academic achievement. She completed her anesthesia residency training at Beth Israel Deaconess Medical Center (Harvard) in Boston. Dr. Chahal did her Pain Management Fellowship at New York Presbyterian/ Weill Cornell Medical Center in NYC. She is board certified by the American Board of Anesthesiology for both anesthesia and pain medicine.

She treats a wide variety of pain diagnoses and has expertise in many procedures including spinal cord stimulators, transforaminal epidural injections, rhizotomies, ultrasound guided nerve blocks, regenerative treatments and botox.

Dr. Chahal's philosophy is use every pain management option available to help patients ease their pain and "get their life back."

The Woodbridge Main Library is located at 1 George Frederick Plaza in Woodbridge, NJ. If you have any questions or need any further information please contact us at 732-634-4450 or visit our website -www.woodbrigelibrary.org.

More:
Learn How You Can Treat Your Pain with Regenerative Medicine! - Patch.com

New Drug Benefits Patients With Myeloma Who Are Resistant to All Therapies – Dana-Farber Cancer Institute

Earlier this year, a novel drug became the first agent to receive U.S. Food and Drug Administration (FDA) approval for patients with multiple myeloma who have exhausted all types of currently available therapies, including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies.

A clinical trial found that 26.2 percent of such patients responded with significant shrinkage of their disease, including complete responses, and a median survival of 8.6 months despite their highly refractory disease.

The drug, selinexor or XPOVIO, developed by Karyopharm Therapeutics of Newton, Massachusetts, is a pill given with low-dose dexamethasone. Its currently being tested in a larger trial in combination with other drugs, such as bortezomib, to determine if it can improve outcome in myeloma.

Its novel mechanism of action and ability to overcome highly resistant disease is striking, says Paul Richardson, MD, clinical program leader and director of clinical research in the Jerome Lipper Multiple Myeloma Center at Dana-Farber, and co-senior author of a report on the study in The New England Journal of Medicine. He and other Dana-Farber investigators were involved in the preclinical and clinical research on selinexor.

The accelerated approval of oral XPOVIOmarks an important advance in the treatment paradigm for patients with relapsed refractory multiple myeloma and in my view the drug is an important addition to our therapeutic armamentarium, says Richardson.

Selinexor is the first in a class ofdrugs that bind to a molecule called exportin 1 and block the transport ofseveral cancer-growth proteins from the cell nucleus to the cytoplasm. The drugalso activates tumor-suppressor proteins in the nucleus, leading to apoptosis,or self-destruction, of the cancer cell.

Selinexor earned accelerated approved by the FDA in July 2019 for patients with relapsed or refractory multiple myeloma who received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody drug.

Patients matching this description are known as triple-class refractory, meaning they did not respond satisfactorily to the three main classes of drugs used to treat myeloma. Survival for these patients is extremely short.

The clinical study report in The New England Journal of Medicine published in August included122 patients who had received a median of seven previous treatment regimensincluding chemotherapy, targeted therapy with bortezomib, carfilzomib,lenalidomide, pomalidomide, and monoclonal antibody (daratumumab). Almost allhad undergone stem cell transplant.

Their median age was 65.2 years and had myeloma for a median of 6.6 years; their disease was rapidly worsening, and they were out of options. These individuals represented the growing population of patients who have exhausted available therapies but want to continue with active therapy, say the researchers.

A partial response or better was seen in 26% of patients, including two complete responses (disappearance of the myeloma protein in their blood) and six very good partial responses, and 39% had a minimal response or better. The median duration of response was 4.4 months, median progression-free survival was 3.7 months, and median overall survival was 8.6 months, though in patients who responded the median survival was 15.6 months. Although there was no control group in the study, as in this setting such an approach is very problematic and lacks equipoise, Richardson says that historically, patients like those in the trial have a survival of only two to three months.

Because the window of time to treat such patients was closing rapidly, says Richardson, they started on a high dose of selinexor, with the researchers anticipating the need to reduce doses if adverse effects occurred. This proved to be the case, with 80% of patients having dose modification or interruption because of adverse events. Fatigue, nausea, and decreased appetite were common and low platelet counts occurred in 73% of patients, anemia in 44% of patients, and 22% had low blood sodium levels.

Richardson says the side effects proved manageable with careful supportive care required in this group of patients who were otherwise very ill and had no other treatment options. He notes the FDA approval was based not only on the results of this study, called STORM, but also on early indications of safety from the phase 3 BOSTON study which was recently completed to enrollment.

Continued here:
New Drug Benefits Patients With Myeloma Who Are Resistant to All Therapies - Dana-Farber Cancer Institute

Notice of Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS – Business Wire

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Promethera Biosciences SA (Promethera) and MEDIPAL HOLDINGS CORPORATION (MEDIPAL) today announced that they have entered into a business alliance agreement. In conjunction with todays alliance, MEDIPAL has decided to increase its shareholdings in the Promethera Group. Details follows below.

The purpose of this alliancePromethera has been developing its lead liver cell-derived technology (HepaStem) in an area of high medical need, primarily for Non-alcoholic steatohepatitis (NASH), Acute-on-chronic liver failure (ACLF) and urea cycle disorder (UCD). Promethera completed the recruitment of 24 patients in its Phase 2a study in Acute-on-chronic liver failure (ACLF) in July 2019. The 3 months follow-up data were presented on 10th November at the AASLD 2019 conference (70th American Association for the Study of the Liver Diseases). In addition, the Phase 2a clinical study in patients with late stage NASH with worlds first cell therapy was initiated in May 2019. MEDIPAL will support Promethera in the commercialization of its products in Japan through the subscription to a private placement of new shares on March 20th, 2019, with the aim to expand the products it handles in the regenerative medicine field going forward.

The purpose of this alliance is to further deepen the cooperative relationship between the two companies by providing access to MEDIPALs know-how and capabilities in the distribution of cellular medicines at ultra-low temperatures. MEDIPAL will support Promethera's clinical trials and aims to provide a steady supply after its product launch.

With about 430 cases per year, the percent of patients receiving a liver transplant in Japan is significantly lower than in the US, where some 8,000 patients receive a transplant every year. Rescue solutions for Japanese patients with fatal liver diseases are performing poorly too. An even closer partnership with MEDIPAL will support us in setting up clinical trials in Japan that could positively impact and contribute to a solution for this considerable medical need in Japan. Building on this partnership, we will accelerate the clinical development of HepaStem towards a subsequent market launch in Japan, which will be a meaningful new development for Japanese patients suffering from end-stage liver disease, said Dr John Tchelingerian, President and CEO of Promethera. Mastering the entire supply chain is a key requirement for an off-the-shelf allogeneic cell therapy product, and MEDIPALs expertise and capabilities in this sector will be very valuable in this regard.

Prometheras HepaStem program can potentially become the worlds first therapeutic product using liver stem cells for the treatment of severe liver diseases, commented Shuichi Watanabe, Chief Executive Officer of MEDIPAL. Liver disease prevalence is rising in Japan and around the world due to an increase in obesity and other metabolic syndromes. The need to deliver effective treatments such as Prometheras is expected to augment rapidly. MEDIPALs system enables strict temperature management and traceability by using SDDU (Specialty Drug Distribution Unit: a liquid nitrogen-based ultra-low cold chain system for drug distribution) and has an extensive expertise in this field. We are very pleased with this partnership and the opportunity to support the development and the logistics of this innovative product candidate with our capabilities.

About MEDIPAL HOLDINGS CORPORATION

Head office

2-7-15, Yaesu Chuo-ku Tokyo 104-8461 Japan

Representative

Shuichi Watanabe, Representative Director, President and CEO

Business

As a holding company, MEDIPAL controls, administers and supports the operating activities of companies in which it holds shares in the Prescription Pharmaceutical Wholesale Business; the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business; and the Animal Health Products and Food Processing Raw Materials Wholesale Business, and conducts business development for the MEDIPAL Group.

Website

https://www.medipal.co.jp/english

About Promethera Biosciences S.A.

Head office

Watson & Crick Hill, Rue Granbonpr, 11 B-1435 Mont-Saint-Guibert, Belgium

Representative

John Tchelingerian, PhD, President & CEO

Business

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring patients life-saving treatments to reduce the need for liver transplantation. Promethera develops and manufactures allogeneic cell-based medicines for liver diseases by using regenerative medicine technology.

Website

https://www.promethera.com/

See the original post here:
Notice of Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS - Business Wire

Silencing Of MAGI1 Promotes The Proliferation And Inhibits Apoptosis O | OTT – Dove Medical Press

Yongzhi Lu,1 Wei Sun,2 Liang Zhang,3 Junyao Li4

1Department of Oncology, Qingdao Municipal Hospital, Qingdao, Shandong Province 266000, Peoples Republic of China; 2Department of Neurology, Qingdao Third Peoples Hospital, Qingdao, Shandong Province 266000, Peoples Republic of China; 3Department of Critical Care Medicine, Qingdao Eighth Peoples Hospital, Qingdao, Shandong Province 266000, Peoples Republic of China; 4Department of Emergency, Qingdao Municipal Hospital, Qingdao, Shandong Province 266000, Peoples Republic of China

Correspondence: Junyao LiDepartment of Emergency, Qingdao Municipal Hospital, Qingdao, Shandong Province 266000, Peoples Republic of ChinaEmail wmy_188@126.com

Background: Membrane-associated guanylate kinase (MAGUK) with inverted orientation protein 1 (MAGI1) is a novel member of the MAGUK family with a vital role in tumor progression related to invasion and metastasis. However, the function of MAGI1 in glioma is currently unknown. We therefore analyzed the expression of MAGI1 protein in human glioma samples, glioma cell lines and glioma stem cells (GSCs), and explored its effects on glioma cell proliferation and apoptosis.Methods: MAGI1 expression in glioma tissues was examined by Western blotting and real-time polymerase chain reaction and its relationships with clinical pathological features were analyzed. The effects of MAGI1 knockdown on the proliferation of glioma cell lines and GSCs were detected by CCK8 and colony-formation assays, and apoptosis was assessed by flow cytometry. We also investigated the effects of MAGI1 silencing on protein expression levels of epithelial-mesenchymal transition biomarkers, as well as -catenin, cyclin D1, PTEN and phospho-Akt by Western blotting.Results: MAGI1 was significantly downregulated in glioma tissues and its expression was related to cancer progression. Silencing of MAGI1 in both glioma cell lines and GSCs enhanced proliferation and inhibited apoptosis. MAGI1 knockdown also significantly increased the expression levels of N-cadherin, vimentin, -catenin, cyclin D1 and phospho-Akt and reduced the expression of E-cadherin and PTEN.Conclusions: Our results indicated that MAGI1 might play a vital role in glioma progression and may represent a potential therapeutic target for the treatment of glioma.

Keywords: glioma, MAGI1, -catenin, EMT, proliferation, knockdown

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more here:
Silencing Of MAGI1 Promotes The Proliferation And Inhibits Apoptosis O | OTT - Dove Medical Press

Stem Cell Banking Market 2019: Growth, Trends, Demand, Share, Analysis and Forecast to 2026 – Markets Gazette 24

Stem Cell Banking Marketis expected to reachUSD 5830.41 Million by 2026 fromUSD 1593.9 Million in 2017 during the forecast period. A stem cell bank is a facility, which stores stem cells for future use. Stem cell banking is the process of conserving stem cells at temperatures below the freezing point. These cells used for the treatment of Parkinsons syndrome, cancer, diabetes, heart diseases, and others.

Stem cell banking market is segmented by Type, Banking service, Application, and Geography. Based on service type the sample preservation & storage segment is expected to hold maximum market share during the forecast period due to the increasing adoption of stem cell banking services in key countries, growing numbers of stem cell banks across developing countries, increasing public consciousness about the therapeutic applications of stem cells.

On the basis of application, the personalized banking applications segment is fastest-growing segment owing to increasing adoption of precision medicine across established countries, the growing prevalence of blood & immune system-related disorders amongstnew-borns& children, &growing public worries regarding the clinical abuse of stored stem cell samples.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/13540

North America is expected to hold largest market share during the forecast period. The increasing network of stem cell banking services, ongoing support of stem cell lines for various disease treatment, new technological developments in the field of stem cell collection & preservation techniques, increasing public-private investments for stem cell researches, rising number of stem cell transplantation procedures are pouring the growth of the Stem Cell Banking Market in North America.

Cordlife introduced NICE, a clinically approved non-invasive prenatal test in Indonesia and the Philippines.LifeCodexx AG, a Provider of non-invasive prenatal DNA testing in Europe, declared its partnership with LifeCell International Pvt. Ltd., an Indian mother & baby preventive health care Type, to bring PrenaTesT, qNIPT testing for the first time to India. The qNIPT technology, which detects the presence of foetal trisomy 21 (Down Syndrome) from maternal blood, received CE marking (European Conformity) in December 2016.

Cordlife Group Limited and China Cord Blood Corporation announced that the two companies collaborated in order to support patients across the China, Singapore, Hong Kong, Indonesia, India, the Philippines, and Malaysia to identify suitable cord blood matching units for stem cell therapy.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/13540

Scope of the report Stem Cell Banking Market:

Stem Cell Banking Market by Type:

Umbilical Cord Stem Cell Adult Stem CellEmbryonic Stem Cell Stem Cell Banking Market by Service Type

Storage Analysis Processing Collection & Transportation Stem Cell Banking Market by Application

Cerebral Palsy Thalassemia Cancer Diseases Diabetes Autism Stem Cell Banking Market by region

North America Europe APAC Latin America MEAKey Players Stem Cell Banking Market:

1. CCBC2. CBR Systems, Inc.3. ViaCord4. Esperite5. Vcanbio6. Boyalife7. LifeCell8. Crioestaminal9. RMS Regrow10. Cryo-cell11. Cordlife Group12. PBKM FamiCord13. Cells4life14. Beikebiotech15. StemCyte

MAJOR TOC OF THE REPORT

Chapter One: Stem Cell Banking Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Stem Cell Banking Market Competition, by Players

Chapter Four: Global Stem Cell Banking Market Size by Regions

Chapter Five: North America Stem Cell Banking Revenue by Countries

Chapter Six: Europe Stem Cell Banking Revenue by Countries

Chapter Seven: Asia-Pacific Stem Cell Banking Revenue by Countries

Chapter Eight: South America Stem Cell Banking Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Stem Cell Banking by Countries

Chapter Ten: Global Stem Cell Banking Market Segment by Type

Chapter Eleven: Global Stem Cell Banking Market Segment by Application

Chapter Twelve: Global Stem Cell Banking Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Stem Cell Banking Market Report at:https://www.maximizemarketresearch.com/market-report/stem-cell-banking-market/13540/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email:sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read the rest here:
Stem Cell Banking Market 2019: Growth, Trends, Demand, Share, Analysis and Forecast to 2026 - Markets Gazette 24

4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress – Montana Ledger

Date: 10th 11th March 2020 Location: London UK

Regenerative therapies are proving its acceptance in the potential of cell-based therapies for chronic disorders. Since our past three editions, our aim through this conference is to provide an illustrative approach to recent developments in technologies of bioprocessing of cellular therapies, to process development and addressing qualitative and regulatory hurdles.

In the 4th edition of MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine, we would be focusing on the pre-clinical, manufacturing, clinical and regulatory aspects of cell therapies and regenerative medicine. This Congress event will be held on 10th and 11th March 2020 in London -UK

Get Register and Download the Agenda at https://www.reportsnreports.com/events/4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress/

Key Pointers 4th Annual MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress

Conference Registration

Lets get you sorted! Choose which applies best to you @ https://www.reportsnreports.com/events/4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress/register

The rest is here:
4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress - Montana Ledger